Home » News & Politics » MiNK Therapeutics pioneering iNKT cell therapies to treat cancer and other immune-mediated diseases

MiNK Therapeutics pioneering iNKT cell therapies to treat cancer and other immune-mediated diseases

Written By Proactive Investors on Tuesday, Aug 09, 2022 | 07:30 AM

 
MiNK Therapeutics (NASDAQ:INKT) president and CEO Dr Jennifer Buell speaks to Proactive about how the clinical-stage biopharmaceutical company is pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Buell explained that the company is currently advancing Phase 1 studies for solid tumour cancers and multiple myeloma, while a Phase 1/2 expansion is underway to evaluate agenT-797 in severe ARDS secondary to COVID-19 and influenza.

Disclaimer:
All images, musics and videos copyright are belong to their respective owners. We just put embed contents from Youtube.com and do not host any content in our server. These content(s) may be protected by copyright law or other laws regarding intellectual property of the United States or other countries. Downloading file(s) on this site is just for review purpose. If you love the song, please support the artists by buying the original CD/Cassette or buying the song from iTunes.